Wells Fargo is telling investors to take advantage of weakness in this drugmaker’s shares, maintaining an”overweight" rating and a $295 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE